The ratio of serum free triiodothyronine to free thyroxine in children: a retrospective database survey of healthy short individuals and patients with severe thyroid hypoplasia or central hypothyroidism by Yuji Oto et al.
Oto et al. Thyroid Research  (2015) 8:10 
DOI 10.1186/s13044-015-0023-5RESEARCH Open AccessThe ratio of serum free triiodothyronine to
free thyroxine in children: a retrospective
database survey of healthy short
individuals and patients with severe thyroid
hypoplasia or central hypothyroidism
Yuji Oto, Koji Muroya, Junko Hanakawa, Yumi Asakura and Masanori Adachi*Abstract
Background: The ratio of serum free triiodothyronine (FT3) to free thyroxine (FT4) has been shown to be constant
in healthy adults. However, this ratio has been found to be decreased in athyreotic adult patients on levothyroxine
(L-T4) supplementation. In order to better evaluate thyroid-related pathologies in children as well as to establish a
reference range, we investigated the FT3/FT4 ratio in a pediatric population. Furthermore, we evaluated this ratio in
children with congenital hypothyroidism as well as those with central hypothyroidism.
Methods: A reference range for the FT3/FT4 ratio was obtained from 129 Japanese children (3–17 y) with idiopathic
short stature who were designated as the ‘Control’ group. Patients with congenital hypothyroidism due to athyreosis or
severe thyroid hypoplasia (designated as ‘A/Hypoplasia’), as well as patients with central hypothyroidism (‘Central’),
were recruited from the institutional database. For each group, the mean FT3/FT4 ratio was obtained.
Results: In the Control group, the FT3/FT4 ratio was 3.03 ± 0.38 10−2 pg/ng (mean ± standard deviation) with no
age or gender differences. A/Hypoplasia patients showed a significantly decreased mean FT3/FT4 ratio (2.17 ± 0.33,
P < 0.001) compared to Control patients, with decreased FT3 and elevated FT4 levels. The Central group also showed a
significantly decreased FT3/FT4 ratio (2.55 ± 0.45, P < 0.001) compared to the Control group, with decreased FT3 and
equivalent FT4 levels.
Conclusions: The FT3/FT4 ratio appears to be constant between the ages of 3–17 y. Children on L-T4 due to congenital
thyroid a/hypoplasia or central hypothyroidism have a decreased FT3/FT4 ratio compared to short normal children.
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Triiodothyronine (T3) is the most active form of thyroid
hormone. While one fifth of net T3 production is per-
formed by the thyroid gland, the remaining 80 % is derived
from the extrathyroidal conversion of thyroxine (T4) to
T3, which is mediated by either iodothyronine deiodinase
1 or 2 (DIO 1 or DIO 2, respectively). In contrast, T4 is
produced exclusively in the thyroid gland [1, 2].* Correspondence: madachi@mars.sannet.ne.jp
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(FT3/FT4 ratio) may reflect the degree of extrathyroidal
T4 to T3 conversion activity. Whereas FT3/FT4 ratio
has been reported to be constant in healthy adult indi-
viduals [3], the consistency of this ratio has not yet been
clearly determined in the pediatric population.
Abnormally high or low FT3/FT4 ratios are seen in sev-
eral congenital disorders that may affect peripheral thyroid
hormone economy, such as Allan-Herndon-Dudley syn-
drome (MCT8 deficiency) [4], selenocysteine insertion se-
quence binding protein 2 deficiency [5], and thyroid
hormone resistance [6, 7]. Therefore, investigating thele distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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) applies to the data made available in this article, unless otherwise stated.
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tion, as well as the establishment of a reference range, is of
vital importance.
Decreased FT3/FT4 ratios has been observed in postop-
erative athyreotic adult patients under oral levothyroxine
(L-T4) supplementation [3, 8]. This presents the thera-
peutic problem of setting a target thyroid-stimulating hor-
mone (TSH) range when treating athyreotic populations
with L-T4. It also indicates the potential benefit of com-
bination therapy with L-T4 and liothyronine (L-T3). It is
therefore probable that these same challenges may apply
to children with congenital hypothyroidism, especially
those with athyreosis. Additionally, we anticipated that the
FT3/FT4 ratio may be unbalanced in children with central
hypothyroidism, owing to diminished TSH stimulation on
thyroidal T3 production.
The purpose of this study was twofold: First, to investi-
gate any age-dependent variations in the FT3/FT4 ratio in
the pediatric population without thyroidal morbidity; and
second, to evaluate this ratio in children with congenital
hypothyroidism owing to athyreosis or severe thyroid hy-
poplasia, and in those with central hypothyroidism of any
etiology.
Methods
This study was conducted as a retrospective database
survey of the patients who attended the endocrine unit
in Kanagawa Children’s Medical Center, the regional
children’s hospital near metropolitan Tokyo between
April 2004 and March 2010. The Ethics Committee of
Kanagawa Children’s Medical Center reviewed and ap-
proved the study protocol. Informed consent from the
patients and/or their caregivers was not required.
To obtain a reference range for the FT3/FT4 ratio, 129
patients who were diagnosed with idiopathic short stat-
ure without any underlying morbidities were selected.
Hereafter, this category is referred to as the ‘Control’.
They were divided into 5 groups according to their
chronological ages: 3–5 y, 6–8 y, 9–11 y, 12–14 y, and
15–18 y. For each interval, mean and standard deviation
(SD) of the FT3/FT4 ratio, expressed as 10−2 pg/ng, was
obtained.
Next, we searched for patients with congenital
hypothyroidism due to athyreosis or severe thyroid hypo-
plasia (designated as ‘A/Hypoplasia’). Thyroid morphology
was evaluated by ultrasound imaging and/or scintigraphy
with 123I or 99mTcO4
−. Among all candidate patients, only
those who presented with a TSH value greater than 100
μIU/mL during the neonatal period were selected. For
each patient, the FT3/FT4 ratio obtained at various
ages throughout childhood was extracted from the
database only when the concurrently determined TSH
level was adequate (0.30–5.0 μIU/mL). If a patient had
measured FT3 and FT4 more than once during achronological year, the mean FT3/FT4 ratio for that
age was used.
Finally, patients with central hypothyroidism, whether
congenital or acquired, were enrolled; these were desig-
nated as ‘Central’. As for patients with growth hormone
(GH) deficiency, only GH-replaced patients were included.
In each patient, the FT3/FT4 ratio was selected only when
the FT4 level was adequate (0.80–1.80 ng/dL). As with
congenital hypothyroidism patients, the mean FT3/FT4
ratio at each age was obtained.
During the study period, serum FT3 and FT4 levels
were determined by electrochemiluminescence immuno-
assay (ECLIA) kits: FT3 by Elecsys® FT3II and FT4 by
Elecsys® FT4 (Roche Diagnostics, Tokyo, Japan). Anti-
bodies used for FT3 and FT4 determination were ovine
monoclonal and polyclonal antibodies, respectively.
Serum TSH levels were determined via the ECLIA kit
Elecsys® TSH (Roche Diagnostics).Statistical analysis
Statistical analysis was performed using the SPSS software
(Version 16.0; SPSS, IL, Chicago, USA). Data were com-
pared using paired t-tests with normal distributions. Dif-
ferences between groups were evaluated by the covariance
analysis test. FT3/FT4 ratios lower than −2 SD or higher
than +2 SD were regarded as outliers. A P value less than
0.05 was considered significant.Results
The profiles of the 129 children with idiopathic short
stature (the Control group) are shown in Table 1. Table 2
shows the reference ranges for the FT3/FT4 ratio in
each age group, together with individual FT3 and FT4
values, obtained from the Control group. The FT3/FT4
ratio was constant across each age interval, although a
significant decrease of FT3 was observed in the 12–14 y
age group compared to the 6–8 y age group (P = 0.037).
There was no significant difference between males and
females in the Control group (Table 3).
There were 22 patients with congenital hypothyroidism
due to A/Hypoplasia with neonatal TSH levels greater
than 100 μIU/mL (Table 1). A total of 101 sets of FT3 and
FT4 values obtained with adequate TSH levels (0.30–5.0
μIU/mL) from these patients were utilized for FT3/FT4
ratio calculation.
Results of FT3/FT4 ratio analysis in A/Hypoplasia pa-
tients, with their respective FT3 and FT4 values, are pre-
sented in Table 2 and Fig. 1. For all age intervals, the FT3/
FT4 ratio was significantly lower than that of the respective
Control, whereas the FT4 levels in A/Hypoplasia were sig-
nificantly higher than that of the Control. Although there
was no difference in FT3 levels between A/Hypoplasia and
Control when comparing within each age interval, the
Table 1 Profiles of the three categories of patients enrolled in this study








Control 129 (81) 3.1–17.1 Not applicable 129 2.16 ± 1.03 (0.56–4.96)
A/Hypoplasia 22 (11) 3.0–18.4 125 (25–200) 156 1.81 ± 1.19 (0.30–4.96)
Central 27 (13) 3.0–18.9 100 (50–200) 366 Not applicable
aSee text for the definition of each category
bL-T4: L-thyroxine, in μg per day
cThese numbers represent all the individual FT3 and FT4 measurements taken before averages were calculated. In A/Hypoplasia and Central, the values exceed
the number of patients owing to repetitive measurements
dValues are μIU/mL; mean ± standard deviation
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(P = 0.004, Table 2).
There were 27 patients in the Central group who were
GH sufficient or replete (Table 1). Of these, 11 patients
had congenital hypopituitarism (including 5 with septo-
optic dysplasia) and 16 had acquired hypopituitarism (11
with craniopharyngioma, 4 with germinoma, and 1 with
ROHHADNET syndrome). A total of 145 sets of values
for FT3 and FT4 (where FT4 levels were 0.80–1.80 ng/
dL) were utilized for FT3/FT4 ratio calculation.
In Table 2 and Fig. 1, the FT3 and FT4 values, as well
as the FT3/FT4 ratio, in the Central group are also pre-
sented. The total FT3/FT4 ratio was significantly lower
than that of the Control group, as was the case in all in-
dividual age groups except for the youngest. The FT4
value in the Central group was not different than that of
the Control group, whereas the total FT3 value of the
Central group was significantly lower than that of the
Control group (P = 0.02).
Table 4 depicts a schematic summary of the FT3/FT4
ratio, as well as the levels of FT3 and FT4, in the A/Hy-
poplasia and Central groups compared to the Control
group.Table 2 FT3 and FT4 levels, as well as their ratios, in patient groups
3–5 y 6–8 y
Control (n = 129) n 24 19
FT3 4.11 ± 0.56 4.29 ± 0.43α
FT4 1.36 ± 0.14 1.38 ± 0.11
FT3/FT4 3.02 ± 0.38 3.12 ± 0.31
A/Hypoplasia (n = 22) nb 14 20
FT3 4.15 ± 0.51 3.86 ± 0.42
FT4 1.95 ± 0.20** 1.81 ± 0.31**
FT3/FT4 2.15 ± 0.25** 2.18 ± 0.30**
Central (n = 27) nb 11 31
FT3 3.50 ± 0.48 3.49 ± 0.53**
FT4 1.24 ± 0.23 1.31 ± 0.17
FT3/FT4 2.94 ± 0.58 2.68 ± 0.51*
Values are pg/mL (FT3) and ng/dL (FT4); mean ± standard deviation
αP < 0.05, *P < 0.05; **P < 0.01, compared to control, respectively
bIn A/Hypoplasia and Central, patients underwent repetitive measurements of FT3 a
patients. The same patients may have average independent measurement values inDiscussion
We observed a marked consistency in the FT3/FT4 ratio
(mean, 3.03 ± 0.38) among healthy short Japanese chil-
dren between 3–17 years of age, with no differences
owing to gender. This finding is in line with a previous
study conducted in an adult population by Gullo et al.
[3], which reported a consistent FT3/FT4 ratio with a me-
dian molar ratio of 0.32 (corresponding to 2.71 10−2 pg/ng),
in 3,875 euthyroid subjects (with minor age and gender
variability). The difference in the absolute value of the ratio
between Gullo et al.’s data [3] and ours may be multi-
factorial, owing to both the methodological differences
in hormone detection (particularly the types of the
antibodies used) and ethnic differences that influence
iodine sufficiency.
Our report is the first to specifically investigate the FT3/
FT4 ratio in the pediatric population. While reference
values for FT3 and FT4 in children have been reported
[9–13], these reports did not refer to the FT3/FT4 ratio.
Additionally, most studies provided only the ranges or
centile values of FT3 and FT4, and calculation of the FT3/
FT4 ratio was therefore impractical. More research is
needed to evaluate the distribution of the FT3/FT4 ratioaccording to age
9–11 y 12–14 y 15–18 y Total
31 36 19 129
4.14 ± 0.38 3.89 ± 0.50α 3.93 ± 0.56 4.06 ± 0.50
1.36 ± 0.14 1.33 ± 0.16 1.31 ± 0.10 1.35 ± 0.14
3.07 ± 0.38 2.95 ± 0.35 3.01 ± 0.50 3.03 ± 0.38
22 21 24 101
3.91 ± 0.45 3.84 ± 0.60 3.52 ± 0.60 3.82 ± 0.55*
1.76 ± 0.26** 1.85 ± 0.59** 1.90 ± 0.69** 1.85 ± 0.47**
2.25 ± 0.39** 2.23 ± 0.34** 2.03 ± 0.30** 2.17 ± 0.33**
46 31 26 145
3.51 ± 0.64** 3.63 ± 0.64 3.46 ± 0.54 3.52 ± 0.58**
1.43 ± 0.29 1.45 ± 0.30 1.49 ± 0.25 1.41 ± 0.27
2.49 ± 0.37** 2.52 ± 0.37* 2.37 ± 0.40** 2.55 ± 0.45**
nd FT4. All the values are averaged according to the chronological age of the
more than one age category if they were evaluated over multiple years
Table 3 Gender difference of FT3/FT4 ratio in Control
3–5 y 6–8 y 9–11 y 12–14 y 15–18 y Total
Male n 10 11 19 29 12 81
FT3/FT4 3.03 ± 0.27 3.23 ± 0.32 3.06 ± 0.30 3.02 ± 0.34 3.09 ± 0.37 3.06 ± 0.32
Female n 14 8 12 7 7 48
FT3/FT4 3.02 ± 0.0.46 2.97 ± 0.25 3.08 ± 0.50 2.83 ± 0.16 3.11 ± 0.23 3.02 ± 0.40
Values are mean ± standard deviation
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influence of pubertal development on this ratio also ought
to be investigated, because FT3 levels in the 12–14 y
groups were found to be lower than in the younger age
groups.
The consistency of the FT3/FT4 ratio during childhood
is useful for the screening of several genetic disorders re-
lated to peripheral thyroid hormone metabolism, includ-
ing Allan-Herndon-Dudley syndrome (MCT8 deficiency)
[4], selenocysteine insertion sequence binding protein 2
deficiency [5], thyroid hormone resistance [6, 7], and
others.
Furthermore, evaluating the FT3/FT4 ratio in patients
on L-T4 supplementation due to various thyroidal disor-
ders may be a method of assessing the sufficiency of the
L-T4 therapy. Observing differences of FT3/FT4 ratios
in pathological situations was the main feature of this
study, which is the first to evaluate this ratio in pediatric












Fig. 1 Serum free triiodothyronine (FT3) to free thyroxine (FT4) ratio
distribution in the Control, A/Hypoplasia, and Central groups. In the
A/Hypoplasia and Central groups, the number of dots exceeds the
patients’ number because all the individual FT3/FT4 measurements
with averaging per chronological age groups are included. Note the
significantly decreased FT3/FT4 ratio in both the A/Hypoplasia and
Central groups compared to the Control groupThe FT3/FT4 ratio in patients with A/Hypoplasia,
which is defined by extremely high neonatal TSH levels
(>100 μIU/mL), was significantly lower than that in the
Control group (Table 2 and Fig. 1). As depicted in
Table 4, this decrease is mainly due to the elevation of
the denominator (FT4 level), although a slightly de-
creased numerator (FT3 level) also contributed. This
finding is consistent with recent studies conducted in adult
populations. For example, Ito et al. found that athyreotic
adult patients (n = 51) who underwent total thyroidectomy
for papillary thyroid carcinoma and who are on L-T4 ther-
apy with normal TSH level (0.3–5 μIU/mL) had increased
FT4 and slightly decreased FT3, resulting in a decreased
FT3/FT4 ratio [8]. Additionally, Gullo et al. reported that
29.6 % of 1,811 patients who were thyroidectomised be-
cause of thyroid cancer and were on L-T4 therapy with
TSH levels of 0.4–4.0 μIU/mL, had FT3/FT4 ratios below
the lower limit of euthyroid controls [3].
Elevated FT4 levels in our A/Hypoplasia group and
athyreotic adult patients is expected because, in athyreo-
tic patients, thyroid hormone is solely derived from ex-
ogenous L-T4 whereas thyroidal T3 production is
almost absent. Thus, normalization of TSH is achieved
at the expense of higher FT4 levels. This is the inverse
situation of the increased FT3/FT4 ratio in untreated or
refractory Graves’ disease, where thyroidal T3 produc-
tion is predominant [14].
Ito et al. explained the pathophysiology of decreased
FT3 levels in their athyreotic adult patients as follows
[8]: First, TSH secreting cells have T3 in their cytoplasm
transported directly from the circulation. Second, these
cells also have T3, which is generated from T4 by intracel-
lular deiodinase. Third, referring to a classical study [15],
it was shown that the proportion of the latter T3 is in-
creased in hypothyroid patients on L-T4. Thus, when tar-
get TSH levels are set to approximate the physiologicallyTable 4 Summary of FT3/FT4 ratio and individual levels in
congenital hypoplasia and central hypothyroidism
Congenital thyroid hypoplasiaa Central hypothyroidisma
FT3/FT4 ratio ↓↓ ↓
FT3 ↓ ↓↓
FT4 ↑↑ →
aCompared to the control group
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level. As Gullo et al. pointed out, the reason for this
phenomenon is the inadequacy of peripheral T3 produc-
tion, which cannot compensate for the absent thyroidal
T3 production [3]. This same scenario likely applies to our
A/Hypoplasia patients.
The Central group was also found to have a signifi-
cantly decreased FT3/FT4 ratio compared to the Control
group. This decrease is mainly due to grossly decreased
FT3 levels with maintained FT4 levels, resulting in a less
prominent decrease of the ratio than that found in the
A/Hypoplasia group (Table 2 and Fig. 1). There does not
appear to be a precedent study investigating the FT3/
FT4 ratio in subjects with central hypothyroidism in ei-
ther adult or pediatric populations.
The explanation for decreased FT3/FT4 values in the
Central group is straightforward: As TSH level cannot
be used as a therapeutic guide in patients with central
hypothyroidism [16], they instead undergo L-T4 therapy
to achieve normal FT4 levels. Thus, FT3 levels must be
lower because T3 is generated mainly from the peripheral
conversion of exogenous L-T4 to T3, and thyroidal T3 pro-
duction is diminished under attenuated TSH stimulation.
The clinical significance of the decreased FT3/FT4 ra-
tio in the A/Hypoplasia and Central groups is unclear. It
has been reported that 5–10 % of hypothyroid patients
treated with L-T4 therapy suffered from symptoms indi-
cative of persistent hypothyroidism such as impaired
well-being, diminished cognitive functions, anxiety, and
depression despite adequate TSH suppression [17–19].
Whether these symptoms are related to abnormal FT3/
FT4 ratios is unknown. In clinical trials, L-T4 and L-T3
combination therapy was found to be beneficial in terms
of quality-of-life and the severity of depression, and was
also found to ameliorate tissue hypothyroidism [20, 21].
Alternatively, Ito et al. suggested that TSH-suppressive
doses of L-T4 are required to achieve preoperative native
serum FT3 levels in patients who have undergone total
thyroidectomy [8]. Further studies are required to deter-
mine the significance of decreased FT3/FT4 ratios and
their effects of therapeutic interventions [17].
The main drawback of this study is that the Control
group constituted children with normal short stature.
Although it is clearly more ideal to compare our subjects
to the general population, we could not evaluate thyroid
function in such subjects because of ethical limitations.
In the pediatric field, however, other studies have uti-
lized data obtained from normal short children as refer-
ences [22, 23]. Additionally, all patients in the Control
group underwent thorough evaluation for possible
underlying diseases, including hypothalamic-thyroid axis.
Therefore, we anticipate that the data from the Control
group can be utilized as an alternative to currently used
references.Conclusions
The FT3/FT4 ratio appears to be constant between 3–17
y. Pediatric populations with congenital hypothyroidism
due to severe thyroidal hypoplasia and with central
hypothyroidism with exogenous L-T4 supplementation
were found to have decreased FT3/FT4 ratios compared
to short normal children. The clinical significance of this
finding should be further investigated.
Abbreviations
TSH: Thyroid stimulating hormone; T3: Triiodothyronine; FT3: Free triiodothyronine;
T4: Thyroxine; FT4: Free thyroxine; L-T3: Liothyronine; L-T4: Levothyroxine;
SD: Standard deviation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MA conceptualized and designed the study. MA and YO contributed to the
data collection, analysis, and writing the manuscript. JH, KM, and YA contributed
to preparation of the manuscript by critically analyzing it. All authors read and
approved the final manuscript.
Received: 9 June 2015 Accepted: 30 June 2015
References
1. Brent GA. Mechanisms of thyroid hormone action. J Clin Invest.
2012;122:3035–43.
2. Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R. Thyroidal and
peripheral production of 3,5,3′-triiodothyronine in humans by
multicompartmental analysis. Am J Physiol. 1990;258:E715–26.
3. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. Levothyroxine
monotherapy cannot guarantee euthyroidism in all athyreotic patients.
PLoS One. 2011;6, e22552.
4. Schwartz CE, May MM, Carpenter NJ, Rogers RC, Martin J, Bialer MG, et al.
Allan-Herndon-Dudley syndrome and the monocarboxtylate transporter
gene. Am J Hum Genet. 2005;77:41–53.
5. Di Cosmo C, McLellan N, Liao XH, Khanna KK, Weiss RE, Papp L, et al.
Clinical and molecular characterization of a novel selenocysteine insertion
sequence-binding protein 2 (SBP2) gene mutation (R128X). J Clin Endocrinol
Metab. 2009;94:4003–9.
6. Ferrara AM, Onigata K, Ercan O, Woodhead H, Weiss RE, Refetoff S. Homozygous
thyroid hormone receptor β-gene mutations in resistance to thyroid hormone:
three new cases and review of the literature. J Clin Endocrinol Metab.
2012;97:1328–36.
7. Bochukova E, Schoenmakers N, Agostini M, Schoenmakers E, Rajanayagam
O, Keogh JM, et al. A mutation in the thyroid hormone receptor alpha
gene. N Engl J Med. 2012;366:243–9.
8. Ito M, Miyauchi A, Morita S, Kudo T, Nishihara E, Kihara M, et al. TSH-
suppressive doses of levothyroxine are required to achieve preoperative
native serum triiodothyronine levels in patients who have undergone total
thyroidectomy. Eur J Endocrinol. 2012;167:373–8.
9. Djemli A, Van Vliet G, Belgoudi J, Lambert M, Delvin EE. Reference intervals
for free thyroxine, total triiodothyronine, thyrotropin and thyroglobulin for
Quebec newborns, children and teenagers. Clin Biochem. 2004;37:328–30.
10. Kapelari K, Kirchlechner C, Högler W, Schweitzer K, Virgolini I, Moncayo R.
Pediatric reference intervals for thyroid hormone levels from birth to
adulthood: a retrospective study. BMC Endocr Disord. 2008;8:15.
11. Soldin OP, Jang M, Guo T, Soldin SJ. Pediatric reference intervals for free
thyroxine and free triiodothyronine. Thyroid. 2009;19:699–702.
12. Verburg FA, Kirchgässner C, Hebestreit H, Steigerwald U, Lentjes EG, Ergezinger
K, et al. Reference ranges for analytes of thyroid function in children. Horm
Metab Res. 2011;43:422–6.
13. Iwaku K, Noh JY, Minagawa A, Kosuga Y, Suzuki M, Sekiya K, et al. Determination
of pediatric reference levels of FT3, FT4 and TSH measured with ECLusys kits.
Endocr J. 2013;60:799–804.
Oto et al. Thyroid Research  (2015) 8:10 Page 6 of 614. Yoshimura Noh J, Momotani N, Fukada S, Ito K, Miyauchi A, Amino N. Ratio
of serum free triiodothyronine to free thyroxine in Graves’ hyperthyroidism
and thyrotoxicosis caused by painless thyroiditis. Endocr J. 2005;52:537–42.
15. Silva JE, Larsen PR. Contributions of plasma triiodothyronine and local
thyroxine monodeiodination to triiodothyronine to nuclear triiodothyronine
receptor saturation in pituitary, liver, and kidney of hypothyroid rats. Further
evidence relating saturation of pituitary nuclear triiodothyronine receptors
and the acute inhibition of thyroid-stimulating hormone release. J Clin
Invest. 1978;61:1247–59.
16. Persani L. Clinical review: Central hypothyroidism: pathogenic, diagnostic,
and therapeutic challenges. J Clin Endocrinol Metab. 2012;97:3068–78.
17. Wiersinga WM. Paradigm shifts in thyroid hormone replacement therapies
for hypothyroidism. Nat Rev Endocrinol. 2014;10:164–74.
18. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM.
Psychological well-being in patients on ‘adequate’ doses of l-thyroxine:
results of a large, controlled community-based questionnaire study. Clin
Endocrinol (Oxf). 2002;57:577–85.
19. Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG, et al.
Cognitive functioning and well-being in euthyroid patients on thyroxine
replacement therapy for primary hypothyroidism. Eur J Endocrinol.
2005;153:747–53.
20. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L.
Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy
for clinical hypothyroidism: meta-analysis of randomized controlled
trials. J Clin Endocrinol Metab. 2006;91:2592–9.
21. Nygaard B, Jensen EW, Kvetny J, Jarløv A, Faber J. Effect of combination
therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4
monotherapy in patients with hypothyroidism, a double-blind, randomised
cross-over study. Eur J Endocrinol. 2009;161:895–902.
22. Tanaka T, Hibi I, Shimizu N, Imura H, Tanaka K, Fukata J, et al. Evaluation of
hypothalamo-pituitary-adrenocortical function in children by human
corticotropin-releasing hormone (MCI-028) test. Endocr J. 1993;40:581–9.
23. Tanaka N, Miyamoto J, Hasegawa Y. A response to human chorionic
gonadotropin test in boys with normal gonadal function and with
hypogonadism. Clin Pediatr Endocrinol. 2001;10:147–50.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
